NeuroVision Imaging

Sacramento, United States· Est. 2002

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $4M

Overview

NeuroVision Imaging is a private, venture-backed company addressing critical gaps in the neurology care pathway through a dual-platform strategy. Its core technology, the Afina Retinal Imaging platform, uses AI to detect amyloid signatures in the retina as a non-invasive biomarker for Alzheimer's and Cerebral Amyloid Angiopathy (CAA). Concurrently, the company's BrainHealth.net telehealth platform offers scalable diagnostic and managed services, including patient triage, preventative neurology coaching, genetic testing, and clinical trial matching, aiming to improve access and outcomes in cognitive healthcare.

Alzheimer's DiseaseNeurological DisordersCerebral Amyloid Angiopathy

Technology Platform

Proprietary retinal imaging platform (Afina) with cloud-based AI software to detect amyloid signatures in the retina as a biomarker for Alzheimer's and CAA. Coupled with the BrainHealth telehealth platform for patient screening, triage, preventative care, and care coordination.

Funding History

Total raised:$4M

Grant$500KNational Institutes of HealthApr 15, 2021

Seed$3.5MUndisclosedSep 15, 2020

Opportunities

The recent approval of disease-modifying Alzheimer's therapies creates an urgent need for scalable, accessible diagnostics to identify eligible patients, representing a massive market opportunity for NeuroVision's Afina platform.

Furthermore, the chronic access problems in neurology and the growing focus on preventative care provide a strong tailwind for the company's integrated BrainHealth telehealth and services model.

Risk Factors

The company faces significant clinical validation risk, as widespread adoption of its retinal imaging technology depends on conclusive proof of its correlation with brain pathology and clinical outcomes.

Additionally, securing insurance reimbursement for both its novel diagnostic test and its telehealth services is a major commercial hurdle that could limit growth.

Competitive Landscape

NeuroVision competes in the rapidly evolving Alzheimer's diagnostics space against companies developing blood-based biomarkers (e.g., C2N Diagnostics, Quest Diagnostics) and other digital cognitive assessment tools. In the telehealth and care coordination arena, it faces competition from other digital health platforms and integrated health systems developing their own cognitive care pathways.